25,727 Shares in Henry Schein, Inc. $HSIC Bought by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. bought a new position in Henry Schein, Inc. (NASDAQ:HSIC) during the 4th quarter, HoldingsChannel reports. The fund bought 25,727 shares of the company’s stock, valued at approximately $1,946,000.

Several other hedge funds also recently made changes to their positions in HSIC. Ameriprise Financial Inc. increased its stake in shares of Henry Schein by 3,275.2% in the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after buying an additional 2,199,695 shares during the period. Bank of America Corp DE increased its stake in shares of Henry Schein by 204.2% in the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after buying an additional 668,182 shares during the period. SG Americas Securities LLC increased its stake in shares of Henry Schein by 171.9% in the fourth quarter. SG Americas Securities LLC now owns 820,698 shares of the company’s stock worth $62,028,000 after buying an additional 518,914 shares during the period. Artisan Partners Limited Partnership increased its stake in shares of Henry Schein by 5.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock worth $453,509,000 after buying an additional 370,837 shares during the period. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Henry Schein in the third quarter worth $15,375,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on HSIC shares. Mizuho decreased their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a research note on Monday, May 4th. Wall Street Zen downgraded shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. BTIG Research started coverage on shares of Henry Schein in a research note on Thursday, April 16th. They issued a “neutral” rating on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $86.83.

Henry Schein Stock Down 0.5%

Shares of Henry Schein stock opened at $76.04 on Wednesday. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59. The company’s fifty day simple moving average is $74.49 and its two-hundred day simple moving average is $75.85. The company has a market cap of $8.66 billion, a P/E ratio of 22.97, a PEG ratio of 1.91 and a beta of 0.82. Henry Schein, Inc. has a 12-month low of $61.94 and a 12-month high of $89.29.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. The business had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts anticipate that Henry Schein, Inc. will post 5.32 EPS for the current year.

Insider Activity at Henry Schein

In other Henry Schein news, Director Kurt P. Kuehn sold 2,844 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the transaction, the director directly owned 15,420 shares of the company’s stock, valued at approximately $1,217,563.20. The trade was a 15.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas C. Popeck sold 1,355 shares of the business’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total transaction of $98,630.45. Following the transaction, the chief executive officer directly owned 86,182 shares in the company, valued at approximately $6,273,187.78. The trade was a 1.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 7,043 shares of company stock valued at $551,737 in the last 90 days. 0.89% of the stock is owned by company insiders.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.